Sunshine Biopharma, Inc. (SBFM)

Sunshine Biopharma, Inc. (NASDAQ:SBFM) Sees Significant Growth in Short Interest

Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know

Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio

Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval

Reviewing Foghorn Therapeutics (NASDAQ:FHTX) and Sunshine Biopharma (NASDAQ:SBFM)

Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 35.0% in June